KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.

Br J Clin Pharmacol · 2026-Mar · PMID 41222125

Panel AUC_steady_state_quartiles提取完成待 EXE 对齐验证

EFS

FIGURE 3 EFS Kaplan–Meier plots for durvalumab exposure metrics by quartiles at dose 1 (A) and steady state (B). Abbreviations: AUC, area under the serum concentration–time curve; AUC, dose 1, AUC from time 0 to the end of dosing interval following the first dose; AUC ss , AUC at steady state; C max , maximum concentration; C max , dose 1, C max following the first dose; C max ,ss, C max at steady state; C min , trough concentration; C min , dose 1, C min following the first dosing cycle; C min ,ss, C min at steady state; CI, confidence interval; EFS, event‐free survival; QX, quartile X.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.82
质量通过是
预期曲线5
实际曲线5
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证52026-07-23T17:11:38+00:00